ENTRY       N00038                      Network
NAME        Amplified FGFR to PI3K signaling pathway
DEFINITION  FGFR* -> PI3K -> PIP3 -> AKT -> MTOR
  EXPANDED  (2260v1,2263v1) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475
CLASS       nt06214 PI3K signaling
            nt06261 Gastric cancer
            nt06270 Breast cancer
TYPE        Variant
PATHWAY     hsa05224  Breast cancer
            hsa05226  Gastric cancer
DISEASE     H00031  Breast cancer
            H00018  Gastric cancer
GENE        2260  FGFR1; fibroblast growth factor receptor 1
            2263  FGFR2; fibroblast growth factor receptor 2
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
            207  AKT1; AKT serine/threonine kinase 1
            208  AKT2; AKT serine/threonine kinase 2
            10000  AKT3; AKT serine/threonine kinase 3
            2475  MTOR; mechanistic target of rapamycin
VARIANT     2260v1  FGFR1 amplification
            2263v1  FGFR2 amplification
METABOLITE  C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:24649067
  AUTHORS   Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  TITLE     Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  JOURNAL   Biomed Rep 2:41-52 (2014)
            DOI:10.3892/br.2013.187
REFERENCE   PMID:20179196
  AUTHORS   Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A
  TITLE     FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
  JOURNAL   Cancer Res 70:2085-94 (2010)
            DOI:10.1158/0008-5472.CAN-09-3746
REFERENCE   PMID:23696246
  AUTHORS   Katoh M, Nakagama H
  TITLE     FGF receptors: cancer biology and therapeutics.
  JOURNAL   Med Res Rev 34:280-300 (2014)
            DOI:10.1002/med.21288
REFERENCE   PMID:19387476
  AUTHORS   Katoh M
  TITLE     FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.
  JOURNAL   J Invest Dermatol 129:1861-7 (2009)
            DOI:10.1038/jid.2009.97
REFERENCE   PMID:20836672
  AUTHORS   Katoh M
  TITLE     Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.
  JOURNAL   Expert Rev Anticancer Ther 10:1375-9 (2010)
            DOI:10.1586/era.10.128
///
